Phase II
After their latest trial delivered disappointing results, Pfizer and BioNTech are ready to test if a third dose of their COVID-19 vaccine would trigger an immune response in very young children.
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look.
The agreement between the two companies includes a lead, potential first-in-class preclinical candidate, and research collaboration to jointly develop the additional novel candidates.
Nodexus and Aramis Biosciences will use their funds to expand their company’s pipeline and build their commercialization capabilities.
Researchers have published a study describing how chemotherapy and a drug used to treat cardiac failure is able to regress tumor growth of patients with triple negative breast cancer.
Biopharmaceutical companies across the world are fighting an increasingly important battle against COVID-19: the struggle to treat the disease.
The 63rd ASH Annual Meeting and Exposition is wrapping up today, with dozens providing updates on clinical trials and preclinical research. Here’s a highlight of just a few of those stories.
As of now, six studies related to islatravir are on full clinical hold, while seven are on partial clinical hold. Here are more updates on the development of this drug.
Making its ASH debut this year was Novartis’ T-Charge CAR-T platform. Novartis presented early data from two first-in-human dose-escalation trials: YTB323 and PHE885.
At the ASH meeting, Bristol Myers Squibb and Kite Pharma presented promising data from CAR-T programs aimed at relapsed or refractory large B-cell lymphoma.
PRESS RELEASES